• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Solventum Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    6/25/25 4:34:45 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email
    solv-20250625
    FALSE000196473800019647382025-06-252025-06-25


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): June 25, 2025    
    Solventum Corporation
    (Exact name of registrant as specified in its charter)
    Delaware001-4196892-2008841
    (State or Other Jurisdiction
    of Incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

    3M Center, Building 275-6W
    2510 Conway Avenue East
    Maplewood, MN 55144
    (Address of Principal Executive Offices, including Zip code)

    (651) 733-1110
    (Registrant’s telephone number, including area code)

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.01 per shareSOLVNew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





    Item 1.01
    Entry into a Material Definitive Agreement.

    As previously disclosed, on February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement (the “Initial Agreement”), pursuant to which, subject to the satisfaction or waiver of certain conditions, Buyer agreed to acquire from Solventum certain assets and liabilities related to Solventum’s purification and filtration business.

    On June 25, 2025, Solventum and Buyer entered into an Amended and Restated Transaction Agreement (the “Agreement”) to exclude Solventum’s drinking water filtration business (the “Water Business”) from the scope of the purification and filtration business to be acquired by Buyer and reduce the cash consideration payable for the acquired business at the closing of the transaction from approximately $4.10 billion to approximately $4.00 billion, with net proceeds still intended to be used primarily to pay down debt. The closing purchase price continues to be subject to customary adjustments for closing cash and debt, unpaid transaction expenses and working capital as set forth in the Agreement.

    The Agreement is expected to decrease complexity and potentially accelerate time to close the transaction, which we previously disclosed is anticipated by the end of 2025. In addition, the Agreement creates future value opportunities from the Water Business. Buyer will be entitled to receive a payment of up to $75 million from Solventum either upon a sale of the Water Business or after an agreed upon 3-year period.

    Keeping the Water Business will increase our previously estimated annual EPS accretion of 15 to 20 cents. However, it will also reduce the previously projected improvements to gross margin and operating margin, which were 200 and 100 basis points, respectively. We will share updated estimates during our second quarter earnings call.

    The Agreement is generally consistent with the terms of the Initial Agreement, except for modifications to reflect the removal of the Water Business including non-compete and related provisions and certain reverse services, manufacturing and supply agreements to support the Water Business.

    The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Agreement, a copy of which is attached hereto as Exhibit 2.1, and the terms of which are incorporated herein by reference. The foregoing description of the Agreement is not intended to provide any other factual information about the acquired business, the Water Business, Solventum, Buyer or their respective businesses.

    Forward Looking Statements

    This Current Report on Form 8-K contains statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” and other words and terms of similar meaning. All statements that reflect Solventum’s expectations, assumptions, or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the sale of the business, the satisfaction of closing conditions and the likelihood of consummation of the transaction, the expected time period to consummate the transaction, the anticipated benefits of the transaction, and the anticipated use of proceeds from the transaction. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and changes in circumstances that are difficult to predict. Although Solventum believes that the expectations reflected in any forward-looking statements it makes are based on reasonable assumptions, it can give no assurance that these expectations, including the expected impact of the divestiture of the business, will be attained and it is possible that actual results may differ materially from those indicated by these forward-looking statements due to a variety of



    risks and uncertainties, include, among others, risks related to the ability to realize the anticipated benefits of the divestiture, including the possibility that expected benefits of portfolio optimization will not be realized or will not be realized within the expected time frame; delays in the closing of the transaction due to regulatory approvals or other closing conditions; unfavorable reaction to the divestiture by customers, competitors, suppliers, and employees, making it more difficult to maintain business and operational relationships; disruption from the transaction; significant transaction costs; and other unknown liabilities.

    Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in Solventum’s periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

    Item 9.01
    Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit
    Number
    Exhibit Description
    2.1
    Amended and Restated Transaction Agreement by and between Solventum Corporation as Seller and Thermo Fisher Scientific Inc. as Buyer dated as of June 25, 2025.
    104.1Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: June 25, 2025SOLVENTUM CORPORATION
    By:/s/ Wayde McMillan
    Wayde McMillan
    Executive Vice President and Chief Financial Officer



    Get the next $SOLV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    7/1/2025$90.00Hold → Buy
    Argus
    6/6/2025Sector Weight
    KeyBanc Capital Markets
    5/19/2025$87.00Neutral → Overweight
    Piper Sandler
    12/4/2024$70.00Neutral
    Mizuho
    10/8/2024$82.00Buy
    Stifel
    10/7/2024$71.00Neutral
    Piper Sandler
    9/26/2024Peer Perform
    Wolfe Research
    9/5/2024Neutral
    BTIG Research
    More analyst ratings

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solventum Named a Best Company to Work for by U.S. News & World Report

      Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14 months as a new company Award highlights success in phase one of Solventum's three-phased Transformation Plan ST. PAUL, Minn., June 18, 2025  /PRNewswire/ -- Solventum (NYSE:SOLV), a global leader in innovative medical technology and solutions, today announced U.S. News & World Report has named the company among its 2025-2026 list of Best Companies to Work For, earning top honors in three categories: Best Companies OverallHealth Care and Resear

      6/18/25 10:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Participate in the 2025 Goldman Sachs Health Care Conference

      ST. PAUL, Minn., June 3, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46th Annual Global Health Care Conference on Tuesday, June 10, 2025, beginning at approximately 4:00 p.m. EDT in Miami, FL. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' tou

      6/3/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Reports First Quarter 2025 Financial Results

      Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Financials

    Live finance-specific insights

    See more
    • Solventum Reports First Quarter 2025 Financial Results

      Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

      ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646

      4/17/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance

      Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3%GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41Generated $219 million in cash from operations; free cash flow of $92 millionIntroduces full-year 2025 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 27, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter ended December 31, 2024. "Solventum executed another quarter of solid performance, enabling us to deliver full year 2024 at the high end of our ex

      2/27/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Solventum upgraded by Argus with a new price target

      Argus upgraded Solventum from Hold to Buy and set a new price target of $90.00

      7/1/25 8:13:22 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • KeyBanc Capital Markets initiated coverage on Solventum Corporation

      KeyBanc Capital Markets initiated coverage of Solventum Corporation with a rating of Sector Weight

      6/6/25 8:37:20 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Corporation upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Solventum Corporation from Neutral to Overweight and set a new price target of $87.00

      5/19/25 8:47:51 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/12/24 5:47:11 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/4/24 1:47:43 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cox Carrie Smith converted options into 5,148 shares (SEC Form 4)

      4 - Solventum Corp (0001964738) (Issuer)

      5/15/25 4:23:40 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Hanson Bryan C converted options into 34,315 shares and covered exercise/tax liability with 13,503 shares, increasing direct ownership by 51% to 61,605 units (SEC Form 4)

      4 - Solventum Corp (0001964738) (Issuer)

      5/15/25 4:23:28 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Director Harris Bernard A Jr converted options into 3,564 shares (SEC Form 4)

      4 - Solventum Corp (0001964738) (Issuer)

      5/15/25 4:23:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    SEC Filings

    See more
    • Solventum Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Solventum Corp (0001964738) (Filer)

      6/25/25 4:34:45 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Solventum Corporation

      SD - Solventum Corp (0001964738) (Filer)

      5/30/25 4:09:35 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Solventum Corporation

      10-Q - Solventum Corp (0001964738) (Filer)

      5/9/25 12:24:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    See more
    • Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

      BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

      2/11/25 8:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

      Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

      1/8/25 6:30:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer

      ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

      10/10/24 9:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care